As Jazz Pharmaceuticals Plc (JAZZ) Stock Price Rose, Shareholder Van Eck Associates Decreased Its Position; Usa Compression Partners LP (USAC) Share Price Declined While Hite Hedge Asset Management Has Upped Stake

June 18, 2018 - By Maria Brooks

USA Compression Partners, LP (NYSE:USAC) Logo

Hite Hedge Asset Management Llc increased its stake in Usa Compression Partners Lp (USAC) by 338.14% based on its latest 2018Q1 regulatory filing with the SEC. Hite Hedge Asset Management Llc bought 95,261 shares as the company’s stock declined 0.11% with the market. The hedge fund held 123,433 shares of the public utilities company at the end of 2018Q1, valued at $2.09 million, up from 28,172 at the end of the previous reported quarter. Hite Hedge Asset Management Llc who had been investing in Usa Compression Partners Lp for a number of months, seems to be bullish on the $1.64B market cap company. The stock decreased 0.24% or $0.04 during the last trading session, reaching $16.9. About 2.01M shares traded or 588.88% up from the average. USA Compression Partners, LP (NYSE:USAC) has risen 11.89% since June 18, 2017 and is uptrending. It has underperformed by 0.68% the S&P500. Some Historical USAC News: 09/03/2018 – USA Compression Partners Short-Interest Ratio Up 66% to 9 Days; 09/03/2018 – USA COMPRESSION PARTNERS, LP REPORTS PRICING OF $725M OFFERING; 05/03/2018 – USA COMPRESSION PARTNERS OUTLOOK STABLE BY FITCH; 09/05/2018 – USA COMPRESSION PARTNERS LP USAC.N – ADJUSTED EBITDA RANGE OF $310.0 MLN TO $330.0 MLN IS EXPECTED FOR FY18; 09/05/2018 – USA COMPRESSION PARTNERS LP – QTRLY BASIC AND DILUTED NET LOSS PER COMMON UNIT $ 0.23; 09/05/2018 – USA Compression Partners Sees 2018 Loss $50M-Loss $30M; 09/05/2018 – USA Compression Partners 1Q EBITDA $44.1M; 09/05/2018 – USA Compression Partners Sees 2018 EBIT $310M-EBIT $330M; 09/05/2018 – USA Compression Partners 1Q Loss/Shr 23c; 19/04/2018 – DJ USA Compression Partners LP, Inst Holders, 1Q 2018 (USAC)

Van Eck Associates Corp decreased its stake in Jazz Pharmaceuticals Plc (JAZZ) by 10.78% based on its latest 2018Q1 regulatory filing with the SEC. Van Eck Associates Corp sold 9,366 shares as the company’s stock rose 11.92% while stock markets declined. The institutional investor held 77,553 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $11.71 million, down from 86,919 at the end of the previous reported quarter. Van Eck Associates Corp who had been investing in Jazz Pharmaceuticals Plc for a number of months, seems to be less bullish one the $10.69B market cap company. The stock increased 0.49% or $0.87 during the last trading session, reaching $178.1. About 514,457 shares traded or 3.31% up from the average. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has risen 8.53% since June 18, 2017 and is uptrending. It has underperformed by 4.04% the S&P500. Some Historical JAZZ News: 08/05/2018 – JAZZ PHARMACEUTICALS PLC – UPDATED FINANCIAL GUIDANCE FOR 2018; 09/05/2018 – Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences; 22/05/2018 – Moody’s Assigns Ba1 To Jazz Pharma’s Senior Secured Credit Facilities; 01/05/2018 – Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive; 15/05/2018 – Jazz Pharma Presenting at Bank of America Conference Tomorrow; 14/03/2018 – New Research: Key Drivers of Growth for Jazz Pharmaceuticals, Armstrong World Industries, Banco Latinoamericano de Comercio Ext; 15/05/2018 – Partner Management Buys New 1.9% Position in Jazz Pharma; 19/03/2018 – JAZZ PHARMACEUTICALS PLC JAZZ.O : MORGAN STANLEY RAISES TO OVERWEIGHT FROM EQUAL-WEIGHT; 08/05/2018 – JAZZ PHARMA 1Q REV. $445M, EST. $434.5M; 01/05/2018 – JAZZ XYREM SNDA FOR CATAPLEXY IN PEDIATRIC NARCOLEPSY

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Prnewswire.com which released: “Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS” on May 24, 2018, also Prnewswire.com with their article: “Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference” published on June 05, 2018, Seekingalpha.com published: “Key events next week – healthcare” on June 01, 2018. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: Nasdaq.com and their article: “3 Biotechs on the FDA’s Naughty List That Should Be on Investors’ Buy Lists” published on May 22, 2018 as well as Nasdaq.com‘s news article titled: “Report: Exploring Fundamental Drivers Behind Mitel Networks, Celestica, CoreCivic, Inc., Jazz Pharmaceuticals, Open …” with publication date: June 04, 2018.

Since January 12, 2018, it had 0 insider purchases, and 21 sales for $5.70 million activity. Young Matthew P. sold $850,212 worth of stock. 3,760 Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares with value of $620,400 were sold by WILSON KAREN J. The insider MILLER MICHAEL PATRICK sold 200 shares worth $32,936. On Thursday, March 1 the insider Treacy Paul sold $122,446.

Investors sentiment decreased to 1.02 in Q1 2018. Its down 0.07, from 1.09 in 2017Q4. It turned negative, as 29 investors sold JAZZ shares while 96 reduced holdings. 44 funds opened positions while 84 raised stakes. 51.95 million shares or 1.94% less from 52.98 million shares in 2017Q4 were reported. Hillsdale Invest Mgmt, a Ontario – Canada-based fund reported 300 shares. Raymond James Advsr Inc holds 0.01% or 8,647 shares. Cwm Lc holds 90 shares or 0% of its portfolio. Pub Employees Retirement Association Of Colorado holds 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 9,691 shares. 683,050 were reported by State Street. Sei Invs owns 9,698 shares. Bingham Osborn & Scarborough Llc, California-based fund reported 15,412 shares. Geode Capital Mngmt Ltd Co has 443,317 shares. Manufacturers Life Ins The reported 377 shares. Gratry & Ltd Liability holds 1.41% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 6,763 shares. Contravisory Mgmt stated it has 0% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Envestnet Asset Management Inc has 748 shares for 0% of their portfolio. Parametric Assocs Limited Co owns 45,176 shares. Jpmorgan Chase And reported 0.05% stake. Tiaa Cref Inv Management Ltd Liability Corporation invested in 0.13% or 1.24M shares.

Among 23 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 19 have Buy rating, 0 Sell and 4 Hold. Therefore 83% are positive. Jazz Pharmaceuticals has $229 highest and $124 lowest target. $181.09’s average target is 1.68% above currents $178.1 stock price. Jazz Pharmaceuticals had 85 analyst reports since August 3, 2015 according to SRatingsIntel. The company was initiated on Wednesday, October 18 by FBR Capital. Cowen & Co maintained the stock with “Buy” rating in Friday, September 22 report. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given on Wednesday, May 11 by Mizuho. The rating was maintained by Wells Fargo with “Buy” on Wednesday, November 8. The firm has “Buy” rating by Deutsche Bank given on Wednesday, August 9. The rating was maintained by Piper Jaffray on Tuesday, August 8 with “Buy”. On Tuesday, January 2 the stock rating was maintained by Stifel Nicolaus with “Buy”. The company was maintained on Wednesday, June 7 by BMO Capital Markets. FBR Capital maintained the stock with “Buy” rating in Thursday, May 10 report. Morgan Stanley initiated the shares of JAZZ in report on Thursday, October 5 with “Hold” rating.

Van Eck Associates Corp, which manages about $30.53 billion and $20.12B US Long portfolio, upped its stake in Iamgold Corp (NYSE:IAG) by 210,472 shares to 61.14M shares, valued at $317.31M in 2018Q1, according to the filing. It also increased its holding in Balchem Corp (NASDAQ:BCPC) by 8,150 shares in the quarter, for a total of 60,196 shares, and has risen its stake in Technipfmc Plc.

Analysts await Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to report earnings on August, 14. They expect $2.87 earnings per share, up 66.86% or $1.15 from last year’s $1.72 per share. JAZZ’s profit will be $172.18M for 15.51 P/E if the $2.87 EPS becomes a reality. After $2.63 actual earnings per share reported by Jazz Pharmaceuticals plc for the previous quarter, Wall Street now forecasts 9.13% EPS growth.

Among 8 analysts covering USA Compression Partners LP (NYSE:USAC), 4 have Buy rating, 2 Sell and 2 Hold. Therefore 50% are positive. USA Compression Partners LP had 30 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of USA Compression Partners, LP (NYSE:USAC) has “Outperform” rating given on Friday, September 9 by FBR Capital. The firm has “Hold” rating given on Monday, April 24 by RBC Capital Markets. The stock has “Overweight” rating by JP Morgan on Tuesday, February 13. The rating was maintained by Janney Capital with “Buy” on Wednesday, April 18. RBC Capital Markets maintained the shares of USAC in report on Wednesday, November 8 with “Hold” rating. As per Friday, September 1, the company rating was initiated by Janney Capital. The firm has “Neutral” rating given on Tuesday, July 28 by JP Morgan. As per Monday, January 11, the company rating was downgraded by Barclays Capital. The firm earned “Hold” rating on Sunday, October 29 by RBC Capital Markets. On Monday, March 5 the stock rating was upgraded by Janney Capital to “Buy”.

Hite Hedge Asset Management Llc, which manages about $778.61 million and $458.88 million US Long portfolio, decreased its stake in Eqt Midstream Partners Lp (NYSE:EQM) by 76,891 shares to 59,080 shares, valued at $3.49 million in 2018Q1, according to the filing. It also reduced its holding in Golar Lng Ltd Bermuda (NASDAQ:GLNG) by 58,854 shares in the quarter, leaving it with 817,305 shares, and cut its stake in Antero Midstream Partners Lp (NYSE:AM).

Investors sentiment increased to 1.23 in Q1 2018. Its up 0.14, from 1.09 in 2017Q4. It increased, as 7 investors sold USAC shares while 15 reduced holdings. 12 funds opened positions while 15 raised stakes. 56.12 million shares or 16.76% less from 67.43 million shares in 2017Q4 were reported. Albert D Mason Incorporated reported 28,601 shares or 0.36% of all its holdings. Wealthtrust holds 0% or 142 shares. First Advisors LP owns 432,717 shares. Perella Weinberg Partners Mngmt Ltd Partnership invested in 447,907 shares or 0.34% of the stock. Ftb Advisors owns 0% invested in USA Compression Partners, LP (NYSE:USAC) for 200 shares. Morgan Stanley invested in 611,672 shares or 0% of the stock. Carlyle Grp Limited Partnership holds 17.49% in USA Compression Partners, LP (NYSE:USAC) or 25.09M shares. First Republic Inv Mgmt Incorporated holds 91,710 shares. Fincl Gru holds 0.21% or 129,871 shares. The Illinois-based Guggenheim Limited Company has invested 0% in USA Compression Partners, LP (NYSE:USAC). Barclays Plc owns 7,577 shares or 0% of their US portfolio. Harvest Fund Advsr Ltd Company accumulated 1.73M shares. Royal Bankshares Of Canada invested in 31,715 shares or 0% of the stock. Tower Rech Ltd Company (Trc) owns 1,893 shares. Renaissance Techs holds 0% of its portfolio in USA Compression Partners, LP (NYSE:USAC) for 171,400 shares.

USA Compression Partners, LP (NYSE:USAC) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>